Opexa Therapeutics, Inc.

Opexa Pharmaceuticals, Inc.

Baylor College of Medicine

Jingwu Z Zang

Cross-reactive T cells recognizing both MBPand HHV-6peptides represent a significant subset of T cells with some degree of TCR degeneracy. It appears that the recognition of the cross-reactive T cells has a less stringent requirement for the flanking residues of the two peptides. In contrast, these flanking residues are critical for the T cell recognition of mono-specific T cells. The association between HHV-6 and autoreactive immune responses to MBP indicates that cross-reactive T cells, peptides from the V-D-J region of the T cell receptor from autoreactive T cells, and antiviral agents may prevent or treat MS.

Isolation and identification of cross-reactive T cells

The present invention relates to improved autologous T cell vaccines and methods for their production. The invention is also directed to methods for treating T cell associated diseases such as multiple sclerosis are rheumatoid arthritis using autologous T cell vaccines.

Growing community of inventors

Missouri City, TX, United States of America

Jingwu Z Zang